Key takeaways
- • Trial: SURPASS-2 (NCT03987919) — Phase 3, 1,879 participants over 40 weeks.
- • Drug studied: Mounjaro (Tirzepatide) — FDA-approved branded product.
- • Primary endpoint: Change in HbA1c from baseline to week 40 vs active comparator semaglutide 1mg
- • Key result: HbA1c reduction 2.01% (5mg), 2.24% (10mg), and 2.30% (15mg) tirzepatide vs 1.86% semaglutide 1mg
- • Published: New England Journal of Medicine, 2021.
Study design
SURPASS-2 was a phase 3 randomized controlled trial enrolling 1,879 participants over 40 weeks. The trial studied Mounjaro (Tirzepatide) for type 2 diabetes and was published in New England Journal of Medicine in 2021.
Primary endpoint
Change in HbA1c from baseline to week 40 vs active comparator semaglutide 1mg
Key results
| Measure | Value |
|---|---|
| Headline result | HbA1c reduction 2.01% (5mg), 2.24% (10mg), and 2.30% (15mg) tirzepatide vs 1.86% semaglutide 1mg |
| HbA1c reduction (highest dose arm) | -2.30 percentage points |
| Participants | 1,879 |
| Duration | 40 weeks |
| Phase | Phase 3 |
Citation
SURPASS-2. Published in New England Journal of Medicine, 2021.
GLP1Zoom did not conduct this trial. We summarize published primary literature. For verbatim methods and full results, consult the primary publication and the ClinicalTrials.gov registry record.
Related
- Mounjaro drug page — pricing, FDA status, side effects, alternatives
- All tirzepatide trials
- GLP-1 clinical trials database
Other Mounjaro trials
Other Tirzepatide trials
- SURMOUNT-1 (Zepbound) — Mean weight loss 15
- SURMOUNT-2 (Zepbound) — Mean weight loss 12
- SURMOUNT-3 (Zepbound) — Additional 18
- SURMOUNT-4 (Zepbound) — Continued tirzepatide arm lost additional 5
Important: This trial was conducted on the FDA-approved branded product Mounjaro. Compounded versions of Tirzepatide have NOT been studied in equivalent randomized controlled trials, and their efficacy and safety profile may differ.
GLP1Zoom is an affiliate-only comparator. We cite published trials; we do not conduct them. This page is informational and is not a substitute for personalized medical advice — always confirm any treatment decision with your prescribing clinician. Full disclaimer.